Company Sponsored Sessions

Thursday, March 12, 2009
07:30 - 08:30
Hall B
Lundbeck - Meet the Expert Breakfast Session - Alzheimer's Disease and Parkinson's Disease dementia - Diagnostic and therapeutic challenges
Expert:
M. Emre, Turkey

Thursday, March 12, 2009
10:00 - 10:40
Affiris GmbH - A new generation of vaccines: targeting AD, PD & Co!
Hall C 
Chairpersons: F. Mattner, Austria
                       E. Masliah, USA

The AFFITOPE-/mimotope approach:  A novel and safe vaccination strategy for neurodegenerative diseases
M. Mandler, Austria

Safety, tolerability and immunogenicity of AFFITOPE vaccines AD01 and AD02 in first-in-man studies in Alzheimer patients
A. Schneeberger, Austria

Immunotherapy for AD & PD: Effects on neuropathology
E. Masliah, USA

Thursday, March 12, 2009
11:20 - 13:00
Wyeth / Elan Symposium: Targeting the Molecular Pathways of AD: Rationale and Outcomes for Disease Modification Strategies

 ACTIVITY INFORMATION

Hall A

Chairpersons's overview: Redefining Alzheimer's Disease
G. Waldemar, Department of Neurology, Memory Disorders Research Unit, Copenhagen University Hospital, Copenhagen, Denmark

Insights into the molecular pathways of Alzheimer's Disease
N. Robakis, Slaner Professor for AD Research, Director Center for Mol. Biology and Genetics of Neurodegeneration, Mount Sinai School of Medicine, New York, USA

Emerging therapies in Alzheimer's Disease
R.S. Doody, Effie Marie Cain Chair in AD, Baylor College of Medicine, Houston, TX, USA

Early management of Alzheimer's Disease
Faculty Panel Discussion and Audience Q&A

Friday, March 13, 2009
07:30 - 08:30 
Lundbeck / Teva Meet the Expert Breakfast Session: Early diagnosis and initiation of treatment challenges in PD and the rationale for initiating treatment as early as possible in the management of Parkinson's Disease
Hall B
Expert:
J. Kulisevsky, Spain

Friday, March 13, 2009
10:00 - 10:50
Cognitive Drug Research and Forenap: Current Trends in Dementia Trials: Guidelines, Imaging Biomarkers and Cognitive Tests
Hall C

The importance of assessing executive function in the dementias
R. Bullock, UK

New advances in Alzheimer's disease guidelines and technologies
P. Danjou, UK 

The EMEA/CHMP 2008 Dementia guidelines; implications for cognitive testing in drug development
K. Wesnes, UK

Friday, March 13, 2009
11:20 - 13:00
Medivation - Mitochondria: An Emerging Therapeutic Focus in Neurodegenerative Diseases
Hall A
Chairperson: B. Winblad, Sweden 

Molecular basis for Neurodegenerative diseases
P. Mecocci, Italy

Pharmacological modulation of mitochondrial function in aging and  neurodegeneration
M. Ankarcrona, Sweden

Novel targets in the treatment of Alzheimer’s Disease
R. Doody, USA

Development of novel therapeutics for Huntington’s Disease
K. Kieburtz, USA

New developments in the diagnosis and treatment of Parkinson’s Disease
W. Olanow, USA

Friday, March 13, 2009
17:00 - 18:30
Probiodrug AG - Pyroglutamated Abeta and Neuroinflammation: Targeting
Fundamentals of AD Pathogenesis by QC inhibition
Hall B

On the discovery, localization and properties of pGlu-Abeta peptides
T. Saido, Japan

pGlu Abeta, localization, toxicity, and prevention of formation by QC-inhibition
S. Schilling, Germany

Treatment of AD-pathology in different mouse models by QC-inhibitors
S. Rossner, Germany

Animal models of molecular mechanism of AD-pathology
T. Bayer, Germany

On the Localization of QC and pGlu peptides in mammalian brain
C. Lemere, USA

Localization of QC in neurons and glia cells
S. von Hörsten, Germany

Chemokine-mediated inflammatory events - understanding neuroinflammation in AD
H. Cynis, Germany

Uncovering the pathways leading to toxic pGlu Abeta peptides
H-U. Demuth, Germany

Saturday, March 14, 2009
09:10 -10:50
Noscira - GSK3 as a Molecular Target in the Treatment of Alzheimer’s Disease
Hall C